2021
DOI: 10.21037/atm-20-5404
|View full text |Cite
|
Sign up to set email alerts
|

A phase III study on neoadjuvant chemotherapy versus neoadjuvant toripalimab plus chemotherapy for locally advanced esophageal squamous cell carcinoma: Henan Cancer Hospital Thoracic Oncology Group 1909 (HCHTOG1909)

Abstract: Background: Neoadjuvant chemotherapy (NAC) and neoadjuvant chemoradiotherapy (NACR) are the standard treatments for esophageal squamous cell carcinoma (ESCC). However, the 5-year overall survival (OS) rate is still far from satisfactory. In recent years, immune checkpoint inhibitors (ICIs) have shown promising results in the treatment of ESCC. More than 20 phase II clinical trials have been launched to explore combinations of ICIs in the neoadjuvant setting for ESCC. Based on our phase II clinical trial, a two… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
31
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
9

Relationship

1
8

Authors

Journals

citations
Cited by 37 publications
(31 citation statements)
references
References 33 publications
0
31
0
Order By: Relevance
“…Toripalimab, a new type of recombinant humanized IgG4 monoclonal antibody against PD-1, has shown promising efficacy and safety in a series of clinical studies. 7 , 8 , 9 , 10 However, there is little evidence as to whether a regimen that combines toripalimab with GS would lead to comparable or better outcomes when administered in patients with advanced BTCs.…”
Section: Introductionmentioning
confidence: 99%
“…Toripalimab, a new type of recombinant humanized IgG4 monoclonal antibody against PD-1, has shown promising efficacy and safety in a series of clinical studies. 7 , 8 , 9 , 10 However, there is little evidence as to whether a regimen that combines toripalimab with GS would lead to comparable or better outcomes when administered in patients with advanced BTCs.…”
Section: Introductionmentioning
confidence: 99%
“…Recently, pembrolizumab plus chemotherapy has been recommended as first-line treatment for advanced EC ( 10 ). Considering the promising results in advanced EC, it is reasonable to explore the efficacy and safety of neoadjuvant immunotherapy combined chemotherapy (nICT) ( 11 , 12 ).…”
Section: Introductionmentioning
confidence: 99%
“…Here, we explored the influence of the COVID-19 pandemic and lockdown policies on cancer patients in Henan by interrupted time series (ITS) analysis using autoregressive integrated moving average (ARIMA) models, which take the autocorrelation, underlying long-term trends, and seasonality into consideration. As the only tertiary cancer hospital in Henan, Henan Cancer Hospital has a bed capacity of over 3,000, about 660,000 outpatient visits, and 180,000 hospitalizations annually ( 19 ). Henan Cancer Hospital is an oncology specialist hospital and, therefore, does not admit patients with COVID-19.…”
Section: Introductionmentioning
confidence: 99%